Dataset Information

A longitudinal study defines circulating microRNAs as reliable biomarkers for disease prognosis and progression in ALS human patients

ABSTRACT: A longitudinal study defines circulating microRNAs as reliable biomarkers for disease prognosis and progression in ALS human patients

PROVIDER: PRJNA623200 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Dataset's files

Source:

			Action	DRS
	SRR11484040.fastq.gz	Fastqsanger.gz
	SRR11484041.fastq.gz	Fastqsanger.gz
	SRR11484042.fastq.gz	Fastqsanger.gz
	SRR11484043.fastq.gz	Fastqsanger.gz
	SRR11484044.fastq.gz	Fastqsanger.gz

Items per page:

1 - 5 of 19

Similar Datasets

Project description:Background Amyotrophic Lateral Sclerosis (ALS) is a fatal neurodegenerative disease associated with motor neuron degeneration, muscle atrophy and paralysis. To date, multiple panels of biomarkers have been described in ALS patients and murine models. Nevertheless, none of them has sufficient specificity and thus the molecular signature for ALS prognosis and progression remains to be fully elucidated. Circulating microRNAs (miRNAs) are highly stable molecules that are recently used as promising biomarkers for many types of human cancer and muscle disorders. Here we overcome this limitation through a longitudinal study, analyzing serum levels of circulating miRNAs in ALS patients during the progression of the pathology. Method We performed next-generation sequencing (NGS) analysis and absolute RT quantification of serum samples of 27 ALS patients and 11 healthy control; among them 13 ALS patients were studied every three months till the end of the disease. Results We demonstrated that miR-151a-3p, miR-206 and miR-199a-3p are significantly expressed at the mild, moderate and severe stages of ALS pathology, whereas the expression levels of miR-133a and miR-199a-5p remained low during the whole study and retain diagnostic significance in the moderate and severe stages (miR-133a) and in mild and terminal stages (miR-199a-5p) of the disease. Moreover, we analysed the miRNAs serum levels during the progression of the disease in each patient and we demonstrated that high levels of miR-206, miR-133a, miR-151a-5p, miR-151a-3p can predict a slower clinical decline of patient functionality suggesting that these miRNAs represent good potential prognostic markers for ALS disease. Conclusion This study is the first to perform a longitudinal absolute quantification of circulating miRNAs during ALS disease. We highlighted putative biomarkers for diagnosis, prognosis and disease stage identification of ALS patients providing cut-off threshold for most of the miRNAs analyzed. In addition, our results define a molecular signature of ALS phenotypes that could help to define appropriate enrollments of patients in clinical trials.

Dataset Information

A longitudinal study defines circulating microRNAs as reliable biomarkers for disease prognosis and progression in ALS human patients

Dataset's files

Similar Datasets

OmicsDI is part of the ELIXIR infrastructure

Tweets